[
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "ABL",
        "binding_metric": "IC50",
        "value": "0.4",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "T315I mutant ABL",
        "binding_metric": "IC50",
        "value": "2.0",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "VEGFR",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "PDGFR",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "FGFR",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "EPH receptors",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "SRC families of kinases",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "KIT",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "RET",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "TIE2",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "Ponatinib",
        "protein_target_name": "FLT3",
        "binding_metric": "IC50",
        "value": "0.1-20",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."
    },
    {
        "molecule_name": "larotrectinib",
        "protein_target_name": "TRKA",
        "binding_metric": "IC50",
        "value": "5-11",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nlarotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM."
    },
    {
        "molecule_name": "larotrectinib",
        "protein_target_name": "TRKB",
        "binding_metric": "IC50",
        "value": "5-11",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nlarotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM."
    },
    {
        "molecule_name": "larotrectinib",
        "protein_target_name": "TRKC",
        "binding_metric": "IC50",
        "value": "5-11",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences:\n\nlarotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM."
    },
    {
        "molecule_name": "ibritumomab tiuxetan",
        "protein_target_name": "CD20 antigen",
        "binding_metric": "KD",
        "value": "14 to 18",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe apparent affinity' (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM."
    },
    {
        "molecule_name": "Vorinostat",
        "protein_target_name": "HDAC1, HDAC2, HDAC3, HDAC6",
        "binding_metric": "IC50",
        "value": "<86",
        "unit": "nM",
        "raw_mentions": "Vorinostat inhibits the enzymatic activity of histone deacety lases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50 &lt; 86 nM)."
    }
]